Jordyn Sava is an editor for Targeted Oncology.
Part A of THIO-101 Trial Shows Positive Topline Safety Data in NSCLC
April 12th 2023Topline data from part A of the THIO-101 trial showed that patients treated with THIO plus cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea among patients with non–small cell lung cancer.
Dosing of QBS72S Begins for the Treatment of Brain Metastases of Breast Cancers
April 11th 2023A phase 2, open-label clinical trial is evaluating treatment with QBS72S in patients with histologically-confirmed breast cancer that has developed brain metastases after a prior cytotoxic chemotherapy regimen.
Updated Eligibility Criterion Warranted in Clinical Trials of Patients With ATC
April 11th 2023In a study performed at MD Anderson Cancer Center, there was no significant overall survival impact in patients with anaplastic thyroid cancer who had prior differentiated thyroid cancer, concomitant differentiated thyroid cancer, and prior non thyroid cancers.
Ide-Cel Shows Clinically Meaningful PFS Improvement in Triple-Class-Exposed RRMM
April 10th 2023The phase 3 Karmma-3 trial of ide-cel in patients with triple-class-exposed relapsed/refractory multiple myeloma generated significantly improved progression-free survival and overall response rates vs standard regimens.
Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors
April 7th 2023A first-in-human study is assessing the safety, efficacy, and pharmacokinetics of DK210 as a monotherapy and in combination with immunotherapy, radiotherapy, or chemotherapy for patients with EGFR-expressing solid tumors.
FDA Accepts BLA of HLX02 for Patients With HER2-Expressing Cancers
April 5th 2023Multiple trials and techniques have evaluated treatment with HLX02 compared with trastuzumab. Now, the FDA has accepted the biologics license application HLX02 for patients with HER2-overexpressing metastatic breast cancer, breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma.
BDC-1001 With/Without Nivolumab Elicits Clinical Responses Across Solid Tumors
April 4th 2023Data from a phase 1/2 study of BDC-1001 alone or with nivolumab supports selection of a recommended phase 2 dose, advancement of further phase 2 studies, and assessment of the agent in combination with pertuzumab.
FDA Accepts sNDAs for Encorafenib and Binimetinib for BRAF V600-Mutated NSCLC
April 4th 2023Results from the phase 2 PHAROS trial of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non–small cell lung cancer has led the FDA to accept supplemental new drug applications for the agents. Further data will be presented at an upcoming medical meeting.
ARAMIS Reinforces Findings from ARASENS and Other Studies of Darolutamide in nmCRPC
April 4th 2023In an interview with Targeted Oncology, Neal D. Shore, MD, FACS, gave an overview of previous and updated findings from the ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer.
Link Between pCR and Improved Survival for Patients With Soft Tissue Sarcoma
April 4th 2023Data from an analysis of the combined NRG-RTOG 0630/9514 trials show that pathologic complete response can be used as a prognostic factor for clinical outcomes in future research of patients with soft tissue sarcoma.